JCM Updates on Azithromycin API Export
CHENGDU, China, April 16, 2014 /PRNewswire/ — Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics, and active pharmaceutical ingredients (API), updated regarding the recent progress of the Jiangchuan Macrolide Facility (JCM). JCM has developed a new line of Azithromycin (Azi) API products that support steady monthly export orders to South Asia.
Following a series of tests on quality, purity, intermediates contents, stereochemistry, stability in comparison with the international standards of Azi API, JCM has received monthly orders for manufacturing one of the major intermediates of Azi, Azithromycin amine (Azi Amine) at a competitive international price which varies from month to month according to the market demands and the foreign exchange rate. The monthly orders starting April this year for Azi Amine were estimated at 5-8 tons per month. TPI will provide updates on the development of the Azi Amine export on a quarterly base.
About Azithromycin and its intermediates
Azithromycin (Azi) is a macrolide antibiotic related to erythromycin. It is used primarily to treat various bacterial infections caused by respiratory pathogens, such as Aerobic gram-positive microorganisms and Aerobic gram-negative microorganisms. Azi prevents bacterial cells from manufacturing specific proteins necessary for their survival. Azi is rapidly absorbed and is widely distributed to tissues and becomes concentrated in cells. Peak plasma concentrations are achieved within 2 to 3 hours. Azi Amine is a close intermediate of Azi and enjoys a competitive pricing trends amongst various derivatives of Azi related products.
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing, and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics, and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. TPI’s pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
Tel: +86-28-8551-6696 (Chengdu, China)
Tianyin Pharmaceutical Inc.
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
SOURCE Tianyin Pharmaceutical Inc.